Cotara continues to perform well in trial

05/31/2009 | Medical News Today

Cotara, a targeted monoclonal antibody-based treatment developed by Peregrine Pharmaceuticals, has continued to show efficacy against a lethal form of brain cancer, called glioblastoma multiforme, in a Phase II trial. Trial data showed that the drug candidate has the capacity to target solid tumors and that it has a safe profile. Interim data from a dose confirmation and dosimetry study of the therapy will be presented at the SNM meeting in June.

View Full Article in:

Medical News Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ